Atypical Neuroleptic Malignant Syndrome With Clozapine and Subsequent Haloperidol Treatment
Dear Editor:
Clozapine can cause neuroleptic malignant syndrome (NMS), with a presentation that may be atypical in that it may occur without rigidity, fever, or changes in creatine kinase (CK) (1) . We report a patient who developed atypical NMS while taking clozapine, followed by a similar syndrome while taking haloperidol.
Mr A, aged 22 years, had a 5-year history of disorganized schizophrenia. He had previously failed trials of olanzapine, valproic acid, and risperidone. During an admission for exacerbated symptoms, a trial of clozapine was initiated. Prior to initiation, his white blood cell count (WBC) was slightly elevated, at 13.3 10 9 /L. Neutrophils, blood pressure (BP), and heart rate (HR) were normal. The clozapine was started at 25 mg daily and titrated to 325 mg daily over 16 days, while his risperidone dosage of 5 mg daily was tapered off completely. Atypically, he had mild hypertension (maximum 156/96) on clozapine, which persisted. On day 17 of clozapine treatment, he declined his medication and was observed to be more disorganized.
The following day, he vomited and was diaphoretic, agitated, and delirious, yet afebrile. He became more hypertensive and tachycardic, with marked elevations in his WBC (31.8 10 9 /L), neutrophils (24.8 10 9 /L), and CK (1442 IU/L). There was no rigidity or evidence of an infectious process. We discontinued the clozapine, and he received haloperidol 5 mg, and lorazepam 2 mg, daily. His WBC, neutrophils, BP, and HR all normalized within 24 hours. Over the following week, his delirium resolved and his CK dropped to 361 IU/L. After 5 days on haloperidol, his WBC, neutrophils, and CK suddenly rose again (17 10 9 /L, 12.8 10 9 /L, and 598 IU/L, respectively). He remained normotensive but became tachycardic. We discontinued haloperidol, and his vital signs and laboratory values subsequently normalized. Following a 1-week period of no antipsychotic (AP) treatment, Mr A was started on olanzapine without any further adverse effects.
To our knowledge, this is the first report of an atypical NMS occurring with clozapine and then repeated with another agent. It is possible that the return of this patient's NMS symptoms might have been caused by residual clozapine in his system. However, the resolution of his laboratory abnormalities and symptoms, followed by their recurrence 5 days later, makes this unlikely. Certain individuals may be sensitive to clozapine and its low affinity for dopamine receptors (2) , and this may underlie an incomplete NMS presentation. A multifactorial contribution from neurotransmitters may also explain the basis of atypical NMS (3). Haloperidol is a relatively specific dopamine blocker and the recurrence of NMS while Mr A was taking this medication lends more support to the dopaminergic theory. Nonetheless, this case highlights the possibility that patients taking clozapine may develop atypical NMS. Once NMS is present, subsequent AP medication should be introduced with caution.
